RU2329058C2 - Новые факторы роста фибробластов - Google Patents

Новые факторы роста фибробластов Download PDF

Info

Publication number
RU2329058C2
RU2329058C2 RU2003119657/14A RU2003119657A RU2329058C2 RU 2329058 C2 RU2329058 C2 RU 2329058C2 RU 2003119657/14 A RU2003119657/14 A RU 2003119657/14A RU 2003119657 A RU2003119657 A RU 2003119657A RU 2329058 C2 RU2329058 C2 RU 2329058C2
Authority
RU
Russia
Prior art keywords
fgf
cells
polypeptide
nucleic acid
cell
Prior art date
Application number
RU2003119657/14A
Other languages
English (en)
Russian (ru)
Other versions
RU2003119657A (ru
Inventor
Питер У. БРИНГМАНН (US)
Питер У. БРИНГМАНН
Дейрил ФОЛДС (US)
Дейрил ФОЛДС
Бранислава МИТРОВИЧ (US)
Бранислава МИТРОВИЧ
Субха СРИНИВАСАН (US)
Субха СРИНИВАСАН
Джеймс ОННУФФЕР (US)
Джеймс ОННУФФЕР
Original Assignee
Шеринг Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Шеринг Акциенгезельшафт filed Critical Шеринг Акциенгезельшафт
Publication of RU2003119657A publication Critical patent/RU2003119657A/ru
Application granted granted Critical
Publication of RU2329058C2 publication Critical patent/RU2329058C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2003119657/14A 2000-12-08 2001-12-10 Новые факторы роста фибробластов RU2329058C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25183700P 2000-12-08 2000-12-08
US60/251,837 2000-12-08
US10/005,646 US20020151496A1 (en) 2000-12-08 2001-12-07 Novel fibroblast growth factors
US10/005,646 2001-12-07

Publications (2)

Publication Number Publication Date
RU2003119657A RU2003119657A (ru) 2005-02-27
RU2329058C2 true RU2329058C2 (ru) 2008-07-20

Family

ID=26674594

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003119657/14A RU2329058C2 (ru) 2000-12-08 2001-12-10 Новые факторы роста фибробластов

Country Status (21)

Country Link
US (2) US20020151496A1 (enExample)
EP (1) EP1389237A2 (enExample)
JP (1) JP2005506275A (enExample)
KR (1) KR20040052442A (enExample)
CN (1) CN1518597A (enExample)
AU (1) AU2603402A (enExample)
BG (1) BG107888A (enExample)
BR (1) BR0116507A (enExample)
CA (1) CA2431374A1 (enExample)
CZ (1) CZ20031570A3 (enExample)
EE (1) EE200300269A (enExample)
HU (1) HUP0400657A1 (enExample)
IL (1) IL156259A0 (enExample)
MX (1) MXPA03005142A (enExample)
NO (1) NO20032573L (enExample)
PL (1) PL366158A1 (enExample)
RU (1) RU2329058C2 (enExample)
SI (1) SI21372A (enExample)
SK (1) SK7012003A3 (enExample)
WO (1) WO2002046424A2 (enExample)
ZA (1) ZA200305236B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7253266B2 (en) 1999-07-27 2007-08-07 Curagen Corporation Polypeptides of FGF-CX
US6982250B2 (en) 2000-11-06 2006-01-03 Curagen Corporation Methods of prevention and treatment of inflammatory bowel disease
US7189693B2 (en) 2000-11-06 2007-03-13 Curagen Corporation Treatment of inflammatory bowel disease using fibroblast growth factor CX polypeptides
WO2003059270A2 (en) * 2002-01-15 2003-07-24 Eli Lilly And Company Method for reducing morbidity and mortality in critically ill patients
WO2004090112A2 (en) 2003-04-01 2004-10-21 United States Of America Department Of Veteran's Affairs Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction
WO2004105787A1 (en) * 2003-05-28 2004-12-09 The University Of Kyoto Methods of using combinations of egf-2 and egf-20 to treat central nervous system disorders
US8951966B2 (en) 2011-07-01 2015-02-10 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
EP3798228A1 (en) 2012-11-28 2021-03-31 NGM Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
MX383664B (es) 2012-12-27 2025-03-14 Ngm Biopharmaceuticals Inc Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.
NZ718962A (en) 2013-10-28 2019-12-20 Ngm Biopharmaceuticals Inc Cancer models and associated methods
RS60593B1 (sr) 2014-01-24 2020-08-31 Ngm Biopharmaceuticals Inc Antitela koja vezuju domen 2 beta-kloto i postupci za njihovu upotrebu
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
EP3155005A4 (en) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
SG11201702757YA (en) 2014-10-23 2017-05-30 Ngm Biopharmaceuticals Inc Pharmaceutical compositions comprising peptide variants and methods of use thereof
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
US11370841B2 (en) 2016-08-26 2022-06-28 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
CN107050428B (zh) * 2017-03-23 2020-05-05 温州医科大学 Fgf20药物及其对脑创伤的治疗应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
WO2001092522A2 (en) * 2000-06-01 2001-12-06 Eli Lilly And Company Human fgf-20 nucleic acids and polypeptides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000060085A1 (en) * 1999-04-02 2000-10-12 Millennium Pharmaceuticals, Inc. Fibroblast growth factor-20
EP1224283A2 (en) * 1999-10-22 2002-07-24 Chiron Corporation Human and rat fgf-20 genes and gene expression products
PT1232264E (pt) * 1999-11-18 2009-11-26 Novartis Vaccines & Diagnostic Gene fgf-21 humano e produtos da expressão do gene
JP2004502418A (ja) * 2000-07-03 2004-01-29 キュラジェン　コーポレイション 新規の線維芽細胞増殖因子およびそれをコードする核酸

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
WO2001092522A2 (en) * 2000-06-01 2001-12-06 Eli Lilly And Company Human fgf-20 nucleic acids and polypeptides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
c.1 описания, фиг.1-2. *
с.1 описания. KANDA T. et al. FGF-9 is an autocrine/paracrine neurotrophic substance for spinal motoneurons // Int J Dev Neurosci. 1999 Jun; 17(3): 191-200, реферат, он-лайн. [Найдено в Интернет на www.pubmed.com 23.11.2007]. PATAKY D.M. et al. Fibroblast growth factor treatment produces differential effects on survival and neurite outgrowth from identified bulbospinal neurons in vitro // Exp Neurol. 2000 Jun; 163(2): 357-72, реферат, он-лайн [Найдено в Интернет на www.pubmed.com 23.11.2007]. *
с.2-9, 13-14, пп.6-14 ф-лы. *

Also Published As

Publication number Publication date
JP2005506275A (ja) 2005-03-03
AU2603402A (en) 2002-06-18
WO2002046424A2 (en) 2002-06-13
EP1389237A2 (en) 2004-02-18
SI21372A (sl) 2004-06-30
AU2002226034A2 (en) 2002-06-18
CZ20031570A3 (cs) 2004-01-14
ZA200305236B (en) 2005-06-29
HUP0400657A1 (en) 2006-04-28
CA2431374A1 (en) 2002-06-13
MXPA03005142A (es) 2004-10-15
RU2003119657A (ru) 2005-02-27
KR20040052442A (ko) 2004-06-23
EE200300269A (et) 2003-10-15
US20080057076A1 (en) 2008-03-06
PL366158A1 (en) 2005-01-24
NO20032573L (no) 2003-07-22
NO20032573D0 (no) 2003-06-06
IL156259A0 (en) 2004-01-04
US20020151496A1 (en) 2002-10-17
BR0116507A (pt) 2004-01-06
CN1518597A (zh) 2004-08-04
WO2002046424A3 (en) 2003-11-27
BG107888A (bg) 2004-08-31
SK7012003A3 (en) 2004-04-06

Similar Documents

Publication Publication Date Title
US20080057076A1 (en) Novel fibroblast growth factors
DK2055308T3 (en) PHARMACEUTICALS FOR PROMOTING FUNCTIONAL REGENERATION OF DAMAGED TISSUE
KR100924183B1 (ko) 신규 섬유아세포 성장 인자 (ｆｇｆ23) 및 그의 이용 방법
KR100728405B1 (ko) Ｎｏｇｏ 유전자의 뉴클레오티드와 단백질 서열 및 이들에기초한 방법
CN105828833A (zh) 突变的成纤维细胞生长因子（fgf）1及使用方法
EP1218509A2 (en) Fibroblast growth factor-like polypeptides
JP3438888B2 (ja) 非分裂促進競合性ｈｇｆ拮抗剤
WO1998022499A2 (en) Arretin, a neurite outgrowth modulator, antibodies thereto and uses thereof
WO1998022499A9 (en) Arretin, a neurite outgrowth modulator, antibodies thereto and uses thereof
US8455448B2 (en) Myostatin isoform
WO1998007736A9 (en) Don-1 gene and polypeptides and uses therefor
ES2397327T3 (es) Compuestos asociados a un dominio único de TDF y análogos de los mismos
AU2002226034B2 (en) Fibroblast growth factors
WO2001032197A2 (en) Methods of using lp8, a pdgf-related protein, to treat musculoskeletal disorders
US5750365A (en) Isolated nucleic acid encoding a newt acidic fibroblast growth factor (AFGF)
JP2004504042A (ja) グリコシル化ｖｅｇｆ−ｂ及び可溶性ｖｅｇｆ−ｂの量を増加させるための方法
AU2002226034A1 (en) Fibroblast growth factors
AU2007203341A1 (en) Fibroblast growth factors
HK1068648A (en) Novel fibroblast growth factors
US20020127594A1 (en) Don-1 gene and polypeptides and uses therefor
US6537554B1 (en) Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
CA2335326A1 (en) Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
US20030104573A1 (en) Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
Burroughs Deciphering the Role of Glycine134 in the Human Acidic Growth Factor-1’s Binding to Heparin

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20081211